nach oben

Erschienen in:

20.07.2022 | Original Article

Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light

verfasst von: A. V. Gracheva, E. R. Korchevaya, Yu. I. Ammour, D. I. Smirnova, O. S. Sokolova, G. S. Glukhov, A. V. Moiseenko, I. V. Zubarev, R. V. Samoilikov, I. A. Leneva, O. A. Svitich, V. V. Zverev, Evgeny B. Faizuloev

Erschienen in: Archives of Virology | Ausgabe 11/2022

Einloggen, um Zugang zu erhalten

Abstract

Vaccination against COVID-19 is the most effective method of controlling the spread of SARS-CoV-2 and reducing mortality from this disease. The development of vaccines with high protective activity against a wide range of SARS-CoV-2 antigenic variants remains relevant. In this regard, evaluation of the effectiveness of physical methods of virus inactivation, such as ultraviolet irradiation (UV) of the virus stock, remains relevant. This study demonstrates that the UV treatment of SARS-CoV-2 completely inactivates its infectivity while preserving its morphology, antigenic properties, and ability to induce the production of virus-neutralizing antibodies in mice through immunization. Thus, the UV inactivation of SARS-CoV-2 makes it possible to obtain viral material similar in its antigenic and immunogenic properties to the native antigen, which can be used both for the development of diagnostic test systems and for the development of an inactivated vaccine against COVID-19.

Francis AI, Ghany S, Gilkes T et al (2021) Review of COVID-19 vaccine subtypes, efficacy and geographical distributions. Postgrad Med J. https://doi.org/10.1136/postgradmedj-2021-140654CrossRefPubMed

Marfe G, Perna S, Shukla AK (2021) Effectiveness of COVID-19 vaccines and their challenges (Review). Exp Ther Med. https://doi.org/10.3892/etm.2021.10843CrossRefPubMedPubMedCentral

Picazo JJ (2021) Vacuna frente al COVID-19 [Vaccine against COVID-19]. Rev Esp Quimioter. Spanish. https://doi.org/10.37201/req/085.2021.

Kandimalla R, Chakraborty P, Vallamkondu J, Chaudhary A, Samanta S, Reddy PH, De Feo V, Dewanjee S (2021) Counting on COVID-19 vaccine: insights into the current strategies, progress and future challenges. Biomedicines. https://doi.org/10.3390/biomedicines9111740CrossRefPubMedPubMedCentral

Kozlovskaya LI, Piniaeva AN, Ignatyev GM, Gordeychuk IV, Volok VP, Rogova YV, Shishova AA, Kovpak AA, Ivin YY, Antonova LP, Mefyod KM, Prokosheva LS, Sibirkina AS, Tarasova YY, Bayurova EO, Gancharova OS, Illarionova VV, Glukhov GS, Sokolova OS, Shaitan KV, Moysenovich AM, Gulyaev SA, Gulyaeva TV, Moroz AV, Gmyl LV, Ipatova EG, Kirpichnikov MP, Egorov AM, Siniugina AA, Ishmukhametov AA (2021) Long-term humoral immunogenicity, safety and protective efficacy of inactivated vaccine against COVID-19 (CoviVac) in preclinical studies. Emerg Microbes Infect. https://doi.org/10.1080/22221751.2021.1971569CrossRefPubMedPubMedCentral

WHO Coronavirus (COVID-19) Dashboard | WHO Coronavirus (COVID-19) dashboard with vaccination data. https://covid19.who.int/. Accessed 23 Feb 2022

Gómez-Carballa A, Pardo-Seco J, Bello X, Martinón-Torres F, Salas A (2021) Superspreading in the emergence of COVID-19 variants. Trends Genet. https://doi.org/10.1016/j.tig.2021.09.003CrossRefPubMedPubMedCentral

Nikonova AA, Faizuloev EB, Gracheva AV, Isakov IY, Zverev VV (2021) Genetic diversity and evolution of the biological features of the pandemic SARS-CoV-2. Acta Nat. https://doi.org/10.32607/actanaturae.11337CrossRef

Choi JY, Smith DM (2021) SARS-CoV-2 variants of concern. Yonsei Med J. https://doi.org/10.3349/ymj.2021.62.11.961CrossRefPubMedPubMedCentral

10.

Mathieu E, Ritchie H, Ortiz-Ospina E et al (2021) A global database of COVID-19 vaccinations. Nat Hum Behav 5:947–953. https://doi.org/10.1038/s41562-021-01122-8CrossRefPubMed

11.

Dupont L, Snell LB, Graham C, Seow J, Merrick B, Lechmere T, Maguire TJA, Hallett SR, Pickering S, Charalampous T, Alcolea-Medina A, Huettner I, Jimenez-Guardeño JM, Acors S, Almeida N, Cox D, Dickenson RE, Galao RP, Kouphou N, Lista MJ, Ortega-Prieto AM, Wilson H, Winstone H, Fairhead C, Su JZ, Nebbia G, Batra R, Neil S, Shankar-Hari M, Edgeworth JD, Malim MH, Doores KJ (2021) Neutralizing antibody activity in convalescent sera from infection in humans with SARS-CoV-2 and variants of concern. Nat Microbiol. https://doi.org/10.1038/s41564-021-00974-0CrossRefPubMedPubMedCentral

12.

Tao K, Tzou PL, Nouhin J, Gupta RK, de Oliveira T, Kosakovsky Pond SL, Fera D, Shafer RW (2021) The biological and clinical significance of emerging SARS-CoV-2 variants. Nat Rev Genet. https://doi.org/10.1038/s41576-021-00408-xCrossRefPubMedPubMedCentral

13.

Saito A et al (2021) Enhanced fusogenicity and pathogenicity of SARS-CoV-2 Delta P681R mutation. Nature. https://doi.org/10.1038/s41586-021-04266-9CrossRefPubMedPubMedCentral

14.

Lu L, Mok BW, Chen LL, Chan JM, Tsang OT, Lam BH, Chuang VW, Chu AW, Chan WM, Ip JD, Chan BP, Zhang R, Yip CC, Cheng VC, Chan KH, Jin DY, Hung IF, Yuen KY, Chen H, To KK (2021) Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients. Clin Infect Dis. https://doi.org/10.1093/cid/ciab1041CrossRefPubMedPubMedCentral

15.

COVID-19 vaccine tracker and landscape. https://www.who.int/publications/m/item/draft-landscape-of-covid-19-candidate-vaccines. Accessed 23 Feb 2022

16.

Gao Q, Bao L, Mao H, Wang L, Xu K, Yang M, Li Y, Zhu L, Wang N, Lv Z, Gao H, Ge X, Kan B, Hu Y, Liu J, Cai F, Jiang D, Yin Y, Qin C, Li J, Gong X, Lou X, Shi W, Wu D, Zhang H, Zhu L, Deng W, Li Y, Lu J, Li C, Wang X, Yin W, Zhang Y, Qin C (2020) Development of an inactivated vaccine candidate for SARS-CoV-2. Science. https://doi.org/10.1126/science.abc1932CrossRefPubMedPubMedCentral

17.

Wu Z, Hu Y, Xu M, Chen Z, Yang W, Jiang Z, Li M, Jin H, Cui G, Chen P, Wang L, Zhao G, Ding Y, Zhao Y, Yin W (2021) Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine (CoronaVac) in healthy adults aged 60 years and older: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial. Lancet Infect Dis. https://doi.org/10.1016/S1473-3099(20)30987-7CrossRefPubMedPubMedCentral

18.

Wang H, Zhang Y, Huang B, Deng W, Quan Y, Wang W, Xu W, Zhao Y, Li N, Zhang J, Liang H, Bao L, Xu Y, Ding L, Zhou W, Gao H, Liu J, Niu P, Zhao L, Zhen W, Fu H, Yu S, Zhang Z, Xu G, Li C, Lou Z, Xu M, Qin C, Wu G, Gao GF, Tan W, Yang X (2020) Development of an inactivated vaccine candidate, BBIBP-CorV, with potent protection against SARS-CoV-2. Cell. https://doi.org/10.1016/j.cell.2020.06.008CrossRefPubMedPubMedCentral

19.

Ella R, Reddy S, Blackwelder W, Potdar V, Yadav P, Sarangi V, Aileni VK, Kanungo S, Rai S, Reddy P, Verma S, Singh C, Redkar S, Mohapatra S, Pandey A, Ranganadin P, Gumashta R, Multani M, Mohammad S, Bhatt P, Kumari L, Sapkal G, Gupta N, Abraham P, Panda S, Prasad S, Bhargava B, Ella K, Vadrevu KM, COVAXIN Study Group (2021) Efficacy, safety, and lot-to-lot immunogenicity of an inactivated SARS-CoV-2 vaccine (BBV152): interim results of a randomised, double-blind, controlled, phase 3 trial. Lancet. https://doi.org/10.1016/S0140-6736(21)02000-6CrossRefPubMedPubMedCentral

20.

Zakarya K, Kutumbetov L, Orynbayev M, Abduraimov Y, Sultankulova K, Kassenov M, Sarsenbayeva G, Kulmagambetov I, Davlyatshin T, Sergeeva M, Stukova M, Khairullin B (2021) Safety and immunogenicity of a QazCovid-in^® inactivated whole-virion vaccine against COVID-19 in healthy adults: a single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2021.101078CrossRefPubMedPubMedCentral

21.

Liu C, Mendonça L, Yang Y, Gao Y, Shen C, Liu J, Ni T, Ju B, Liu C, Tang X, Wei J, Ma X, Zhu Y, Liu W, Xu S, Liu Y, Yuan J, Wu J, Liu Z, Zhang Z, Liu L, Wang P, Zhang P (2020) The architecture of inactivated SARS-CoV-2 with postfusion spikes revealed by Cryo-EM and Cryo-ET. Structure. https://doi.org/10.1016/j.str.2020.10.001CrossRefPubMedPubMedCentral

22.

Gracheva AV, Korchevaya ER, Kudryashova AM, Borisova OV, Petrusha OA, Smirnova DI, Chernyshova IN, Svitich OA, Zverev VV, Faizuloev EB (2021) Adaptation of the MTT assay for detection of neutralizing antibodies against the SARS-CoV-2 virus. J Microbiol Epidemiol Immunobiol. https://doi.org/10.36233/0372-9311-136CrossRef

23.

Ramakrishnan MA (2016) Determination of 50% endpoint titer using a simple formula. World J Virol. https://doi.org/10.5501/wjv.v5.i2.85CrossRefPubMedPubMedCentral

24.

Chan JF, Yip CC, To KK, Tang TH, Wong SC, Leung KH et al (2020) Improved molecular diagnosis of COVID-19 by the novel, highly sensitive and specific COVID-19-RdRp/Hel real-time reverse transcription-PCR assay validated in vitro and with clinical specimens. J Clin Microbiol. https://doi.org/10.1128/JCM.00310-20CrossRefPubMedPubMedCentral

25.

Yuan Y, Wang RT, Xia J, Cao HJ (2021) Interventions for preventing influenza: an overview of Cochrane systematic reviews and a Bayesian network meta-analysis. J Integr Med. https://doi.org/10.1016/j.joim.2021.09.001CrossRefPubMedPubMedCentral

26.

Stuurman AL, Marano C, Bunge EM, De Moerlooze L, Shouval D (2017) Impact of universal mass vaccination with monovalent inactivated hepatitis A vaccines—a systematic review. Hum Vaccin Immunother. https://doi.org/10.1080/21645515.2016.1242539CrossRefPubMed

27.

Hegde NR, Gore MM (2017) Japanese encephalitis vaccines: immunogenicity, protective efficacy, effectiveness, and impact on the burden of disease. Hum Vaccin Immunother. https://doi.org/10.1080/21645515.2017.1285472CrossRefPubMedPubMedCentral

28.

Vidor E, Plotkin SA (2013) Poliovirus vaccine—inactivated. Vaccines, 6th edn. Elsevier Saunders, Philadelphia

29.

Xing Y, Schmitt HJ, Arguedas A, Yang J (2017) Tick-borne encephalitis in China: a review of epidemiology and vaccines. Vaccine. https://doi.org/10.1016/j.vaccine.2017.01.015CrossRefPubMed

30.

Schneweis KE, Gruber J, Hilfenhaus J, Möslein A, Kayser M, Wolff MH (1981) The influence of different modes of immunization on the experimental genital herpes simplex virus infection of mice. Med Microbiol Immunol. https://doi.org/10.1007/BF02125526CrossRefPubMed

31.

Cappel R (1976) Comparison of the humoral and cellular immune response after immunization with live, UV inactivated herpes simplex virus and a subunit vaccine and efficacy of these immunizations. Arch Virol. https://doi.org/10.1007/BF01317862CrossRefPubMed

32.

Gao Q, Zhao S, Qin T, Yin Y, Yu Q, Yang Q (2016) Effects of inactivated porcine epidemic diarrhea virus on porcine monocyte-derived dendritic cells and intestinal dendritic cells. Res Vet Sci. https://doi.org/10.1016/j.rvsc.2016.03.023CrossRefPubMed

33.

Zahorska R, Mazur N, Korbecki M (1978) Immunogenicity of UV-inactivated measles virus. Zentralbl Bakteriol Orig A. 240(4):424-30.

34.

Selimov M, Aksenova T, Klyueva E, Gribencha L, Lebedeva I (1978) Evaluation of the inactivated tissue culture rabies vaccine from the Vnukovo-32 strain. Results of its industrial production and field use for post-exposure immunization of man. Dev Biol Stand. 40:57-62.

35.

Marthas ML, Miller CJ, Sutjipto S, Higgins J, Torten J, Lohman BL, Unger RE, Ramos RA, Kiyono H, McGhee JR et al (1992) Efficacy of live-attenuated and whole-inactivated simian immunodeficiency virus vaccines against vaginal challenge with virulent SIV. J Med Primatol. 21(2-3):99-107.

36.

Bresler S, Kolikov V, Katushkina N, Molodkin V, Friedman E, Zheleznova H, Malafeieva L, Peradze T, Beljakov V, Ivanov K (1975) Immunogenicity of inactivated influenza vaccine, purified by adsorption chromatography on porous glas. Med Biol. 53(6):456-61.

37.

Iwata-Yoshikawa N, Uda A, Suzuki T, Tsunetsugu-Yokota Y, Sato Y, Morikawa S, Tashiro M, Sata T, Hasegawa H, Nagata N (2014) Effects of Toll-like receptor stimulation on eosinophilic infiltration in lungs of BALB/c mice immunized with UV-inactivated severe acute respiratory syndrome-related coronavirus vaccine. J Virol. https://doi.org/10.1128/JVI.00983-14CrossRefPubMedPubMedCentral

38.

Lo CW, Matsuura R, Iimura K et al (2021) UVC disinfects SARS-CoV-2 by induction of viral genome damage without apparent effects on viral morphology and proteins. Sci Rep 11:13804. https://doi.org/10.1038/s41598-021-93231-7CrossRefPubMedPubMedCentral

39.

Mathew AM, Mun AB, Balakrishnan A (2018) Ultraviolet inactivation of Chikungunya virus. Intervirology. https://doi.org/10.1159/000490567CrossRefPubMed

40.

Darnell ME, Subbarao K, Feinstone SM, Taylor DR (2004) Inactivation of the coronavirus that induces severe acute respiratory syndrome, SARS-CoV. J Virol Methods. https://doi.org/10.1016/j.jviromet.2004.06.006CrossRefPubMedPubMedCentral

41.

List of Classifications—IARC monographs on the identification of carcinogenic hazards to human. https://monographs.iarc.who.int/list-of-classifications. Accessed 23 Feb 2021

42.

Heilingloh CS, Aufderhorst UW, Schipper L, Dittmer U, Witzke O, Yang D, Zheng X, Sutter K, Trilling M, Alt M, Steinmann E, Krawczyk A (2020) Susceptibility of SARS-CoV-2 to UV irradiation. Am J Infect Control. https://doi.org/10.1016/j.ajic.2020.07.031CrossRefPubMedPubMedCentral

43.

Gu H, Chen Q, Yang G et al (2020) Adaptation of SARS-CoV-2 in BALB/c mice for testing vaccine efficacy. Science. https://doi.org/10.1126/science.abc4730CrossRefPubMedPubMedCentral

44.

Muruato A, Vu MN, Johnson BA, Davis-Gardner ME, Vanderheiden A, Lokugamage K, Schindewolf C, Crocquet-Valdes PA, Langsjoen RM, Plante JA, Plante KS, Weaver SC, Debbink K, Routh AL, Walker D, Suthar MS, Shi PY, Xie X, Menachery VD (2021) Mouse-adapted SARS-CoV-2 protects animals from lethal SARS-CoV challenge. PLoS Biol. https://doi.org/10.1371/journal.pbio.3001284CrossRefPubMedPubMedCentral

45.

Kant R, Kareinen L, Smura T, Freitag TL, Jha SK, Alitalo K, Meri S, Sironen T, Saksela K, Strandin T, Kipar A, Vapalahti O (2021) Common laboratory mice are susceptible to infection with the SARS-CoV-2 beta variant. Viruses. https://doi.org/10.3390/v13112263CrossRefPubMedPubMedCentral

46.

National Research Council (US) (2011) Committee for the update of the guide for the care and use of laboratory animals. Guide for the Care and Use of Laboratory Animals. 8th ed. Washington (DC): National Academies Press (US); 2011.

Titel: Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light
verfasst von: A. V. Gracheva
E. R. Korchevaya
Yu. I. Ammour
D. I. Smirnova
O. S. Sokolova
G. S. Glukhov
A. V. Moiseenko
I. V. Zubarev
R. V. Samoilikov
I. A. Leneva
O. A. Svitich
V. V. Zverev
Evgeny B. Faizuloev
Publikationsdatum: 20.07.2022
Verlag: Springer Vienna
Erschienen in: Archives of Virology / Ausgabe 11/2022
Print ISSN: 0304-8608
Elektronische ISSN: 1432-8798
DOI: https://doi.org/10.1007/s00705-022-05530-7

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Immunogenic properties of SARS-CoV-2 inactivated by ultraviolet light

Abstract

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin

Live-Webinar "Urologie und Sexualmedizin in der Praxis"

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 11/2022

Genetic characterization and evolutionary analysis of canine parvovirus in Tangshan, China

Phylogenetic analysis of torque teno virus in Romania: possible evidence of distinct geographical distribution

Complete genome sequence of a Moroccan isolate of cereal chlorotic mottle virus

Complete genome sequence of Aconitum amalgavirus 1, a distinct member of the genus Amalgavirus

Genetic characterization of a novel HIV‑1 CRF01_AE/ CRF07_BC recombinant form found among men who have sex with men in Baoding City, Hebei Province, China

A novel fungal negative-stranded RNA virus related to mymonaviruses in Auricularia heimuer

Leitlinien kompakt für die Innere Medizin

Neu im Fachgebiet Innere Medizin

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

15% bedauern gewählte Blasenkrebs-Therapie

Costims – das nächste heiße Ding in der Krebstherapie?

Update Innere Medizin